Incidence of infections (all grades) with CFAR therapy by NCI-WG response and course number
| Infection . | No. of courses . | Total no. of infections . | No. of major infections . | Risk per course . |
|---|---|---|---|---|
| Response | ||||
| CR | 191 | 36 | 19 | 0.18 |
| nPR | 9 | 1 | 2 | 0.11 |
| PR | 48 | 7 | 6 | 0.14 |
| NR | 12 | 2 | 0.17 | |
| Course no. | ||||
| 1-3 | 175 | 24 | 8 | 0.14 |
| 4-6 | 85 | 22 | 18 | 0.23 |
| Infection . | No. of courses . | Total no. of infections . | No. of major infections . | Risk per course . |
|---|---|---|---|---|
| Response | ||||
| CR | 191 | 36 | 19 | 0.18 |
| nPR | 9 | 1 | 2 | 0.11 |
| PR | 48 | 7 | 6 | 0.14 |
| NR | 12 | 2 | 0.17 | |
| Course no. | ||||
| 1-3 | 175 | 24 | 8 | 0.14 |
| 4-6 | 85 | 22 | 18 | 0.23 |
Risk per course refers to the total number of infections/number of courses. Major infections refers to pneumonia, sepsis, fever of unknown origin requiring hospitalization.
CFAR indicates alemtuzumab added to FCR; NCI-WG, National Cancer Institute–Working Group; CR, complete remission; nPR, nodular partial remission; PR, partial remission; and NR, no response.